MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)
Clinical trial NCT03932253 · SUSPENDED
Trial details
- NCT number
- NCT03932253
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Status
- SUSPENDED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-21
- Primary completion
- 2023-04-30
- Enrollment
- 79
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.